Connecticut researchers are further investigating the benefits of an Alzheimer’s drug that received praise this past summer as a potential treatment for the disease.
The drug, Dimebon, is a 25-year-old Russian antihistamine that was proven to sustain key functions in Alzheimer’s patients for at least 18 months, MedicalNews reported in July.
Currently, a new clinical trial is underway in Connecticut to see if the results from the summer can be replicated, WTNH Channel 8 reports.
"If [the drug] is disease modifying, if the previous study is replicated, that really raises the possibility that this kind of treatment is actually slowing the degeneration of brain cells.
It’s actually enhancing their survival," Dr Christopher van Dyck, one of the researchers in the study, told the news provider.
According to Channel 9, a different twist to the summer study is examining the impact of the disease on caregivers.
Nancy Cannon is in the trial with her husband Irv, who suffers from Alzheimer’s, and told WTNH since they have been in the study she hasn’t noticed any changes in her husband.
"And because my husband’s progression is so slow, we think maybe, maybe something will happen in time," said Nancy.
© Copyright
